[ivory-search id="184" title="Recordati AJAX Search Form"]

Item Tag: 229/182

Pokemon TCG Roaring Moon ex 229/182 Paradox Rift Holo Ultra Rare Full Art NM

For sale is a powerful and highly collectible Roaring Moon ex 229/182 Ultra Rare from the popular Paradox Rift set! Set: Scarlet & Violet – Paradox Rift. This full art card features the fierce Ancient Pokémon Roaring Moon with vibrant holo artwork that looks incredible in any binder, display case, or graded collection.

Pokemon Team Rocket’s Moltres ex 229/182 Special Illustration Rare TAG 9 Mint

The product is a Pokémon Team Rocket’s Moltres ex 229/182 Special Illustration Rare card from the Pokémon TCG game. This mint-grade 9 card features a unique artwork by Adam Paquette and is authenticated by Professional Sports Authenticator (PSA). With a HP of 220, this Ancient Bird-type Pokémon card is a valuable addition to any collector’s collection. Manufactured by The Pokémon Company in 2025, this English-language card is a sought-after item for fans of the Pokémon franchise.

Pokémon TCG: Team Rocket’s Moltres ex #229/182 Destined Rivals Stamp Promo NM

This product is a Pokémon TCG Team Rocket’s Moltres ex card from the Destined Rivals set, featuring the Ancient Bird type with 220 HP. It is a standard-sized card in English, manufactured by The Pokémon Company in 2025. This full art, holo card is a Secret Ultra Rare with an alternative art design, making it a highly sought-after collectible for Pokémon TCG fans. With its unique features and rarity, this card is a valuable addition to any collector’s deck.

Pokémon TCG Team Rockets Moltres EX Destined Rivals Card 229/182 SIR Stamped

The Pokémon TCG Team Rocket’s Moltres EX Destined Rivals Card 229/182 SIR Stamped is a highly sought-after collectible card featuring the iconic Ancient Bird creature type with 220 HP. Manufactured by The Pokémon Company in 2025, this English-language card from the Sv10: Destined Rivals set is part of the Pokémon TCG game. With a Full Art design and Holo finish, this card is a Special Illustration Rare that is perfect for fans of the Pokémon franchise. Illustrated by Akira Egawa, this card is a valuable addition to any collector’s deck.

Team Rocket’s Moltres ex 229/182 Sv10 Destined Rivals

Card is from 2025 set Destined Rivals. No visible surface or edge damage. Not graded. Slight card curvature from pack. (included in photo) Will ship sleeved, with toploader, and extra packaging support to prevent bending.

You are about to leave this site and visit the recordati global website?

To continue please click the link below.

Visit Global Site

You are about to leave this site and visit the recordati global website?

To continue please click the link below.

Visit Global Site

You are about to leave this site and visit the recordati global website?

To continue please click the link below.

Visit Global Site
Recordati for the planet
A clean environment is essential for people’s well-being: the health of the planet and the health of people is tightly interconnected. Environmental elements, such as air, water, land and climate, all have an impact on the well-being of humans. Placing a focus on people’s health and being sustainable therefore also means prioritising environmental protection and a responsibility towards future generations. This is why the Group ensures that it conducts business in a socially responsible manner and in accordance with sustainable practices, national and international laws, and the expectations of stakeholders.
Recordati for the community
We believe that contributing to the well-being of the community and dedicating part of our resources to acts of solidarity is not merely the fulfilment of company obligations or professional duty, but rather a moral imperative, an essential part of a healthy business capable of growth but at the same time able to support and develop the community in which it operates and make its employees proud.
Value and diversity of our people
At Recordati, we believe in equal opportunities and we guarantee that everyone can achieve their potential. We see diversity as a value and will not tolerate any discrimination based on ethnicity, nationality, gender, sexual orientation, disability, age, political or religious belief, or any other personal characteristics. At Recordati, we work hard to create a safe and inclusive work environment, where we all have our rights to physical and psychological integrity respected on a daily basis, as well as our right to freedom of opinion and association. We recognise that we each have a role to play in the success of our business and we implement staff development policies through which everyone’s contribution and achievements can be appropriately rewarded.
Multiple opportunities
Recordati is uniquely structured to bring treatment options across specialty and primary care, consumer healthcare, and rare diseases. We have fully integrated operations across research and development, chemical and finished product manufacturing through to commercialisation and licensing.
Luigi Longinotti
Managing Director and General Manager EMEA

Luigi Longinotti is Managing Director and General Manager for EMEA at Recordati Rare Diseases, leading the European and Middle Eastern Commercial Operations. He is responsible for Marketing, Medical, Market Access, Regulatory, Manufacturing and Logistics, as well as the enabling functions to support the business, including Compliance and Quality.

 

He joined Recordati in July 2014 as Corporate Portfolio Management Director for Orphan Drugs. In such a role he has been responsible for driving the growth of the rare disease portfolio at Recordati, with his duties ranging from business development to strategic marketing and pipeline project management.

 

Before he joined Recordati, he held senior business and corporate development roles at Chiesi Farmaceutici and Menarini Group where he executed several key asset deals and transactions.

Luigi gained a degree in Economics from the University of Florence and a Master’s degree in Business Innovation from Sant’Anna School of Advanced Studies in Pisa.

Bruno Parenti
Head of LAC Region, Head of Global Endocrinology Franchise

Bruno Parenti is Head of LAC Region at Recordati Rare Diseases, leading the business in Latin America, Asia Pacific and Russia. He has been in this position since 2011, where he spearheaded the expansion of operations around the globe. He recently assumed the additional role of Head of Global Endocrinology Franchise, establishing the new HQ in Basel and building a dedicated organization.

 

Prior to these positions, Bruno spent two years at Recordati Ireland overseeing international sales in the Asia-Pacific region. He served at Chiesi Farmaceutici for two years as Area Manager for the Far East. Earlier in his career, he held commercial roles at Kedrion Biopharmaceuticals where he was responsible for international markets with a focus on Latin America and the Middle East.

Scott Pescatore
Executive Vice President

Scott Pescatore is Vice President and Head of Global Operations at Recordati Rare Diseases.

He holds a Doctor of Pharmacy degree and completed his post-doctoral fellowship in Pharmacology and Drug Development. Dr Pescatore has spent over 20 years working internationally in the pharmaceutical industry, specializing in oncology, haematology and rare diseases.

 

He joined Novartis Oncology US in 2001 where he served in various medical, sales and marketing roles of increasing responsibility. In 2008, he moved to Novartis Oncology UK as Business Franchise Head for solid tumours where he also managed the New Products portfolio. In 2010 he moved to Milan to manage the Region Europe Haematology Franchise where he led the joint venture between Novartis Oncology and Incyte to launch a novel treatment for myeloproliferative disorders. In 2014 he was appointed the Oncology General Manager in Ireland and after three years returned to Milan as General Manager of the Region Europe Rare Disease Business Unit, overseeing operations in 37 markets and focusing on the endocrinology portfolio.

 

Prior to joining Recordati Rare Diseases in 2020, he was Vice President Oncology Business Unit for AstraZeneca Italy where he was responsible for the portfolio of oncology/haematology products including two joint ventures with MSD and Daiichi Sankyo.

You are about to leave this site and visit the recordati global website?

To continue please click the link below.

Visit Global Site